• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白酶体激活剂(PA28)亚基α、β和γ(Ki抗原)在NT2神经前体细胞和HeLa S3细胞中的情况。

Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells.

作者信息

Wójcik C, Tanaka K, Paweletz N, Naab U, Wilk S

机构信息

Department of Pharmacology, Mount Sinai School of Medicine, New York, NY, USA.

出版信息

Eur J Cell Biol. 1998 Oct;77(2):151-60. doi: 10.1016/s0171-9335(98)80083-6.

DOI:10.1016/s0171-9335(98)80083-6
PMID:9840465
Abstract

The catalytic activity of the 20S proteasome can be modulated by endogenous proteins. A proteasome activator protein termed PA28 or 11S regulator, composed of two homologous subunits (alpha and beta) and a separate but related protein termed Ki antigen or PA28gamma have been characterized. To explore the functional relationship of these proteins, NT2 clone D1 human neuronal precursor cells, as well as HeLa S3 cells were labeled by immunofluorescence and immunoelectron microscopy with three different antisera directed against peptides derived from their sequences. It was found that both PA28alpha and PA28beta antisera label the cytoplasm and the nucleoli. In contrast, the PA28gamma antiserum labels the nucleus but not the nucleoli while in the cytoplasm it labels two different classes of structures identified as microtubular-like extensions and inclusion bodies that are most likely autophagosomes. The latter do not contain proteasome delta subunit antigen. The microtubular-like structures colocalize with beta-tubulin, are dispersed by nocodazole and are not affected by brefeldin A treatment. PA28alpha and PA28beta are co-localized in the cell whereas PA28gamma has a different distribution. PA28gamma complexed with the proteasome may serve a function other than or in addition to activation and may also have a proteasome-independent function.

摘要

20S蛋白酶体的催化活性可受内源性蛋白质的调节。一种被称为PA28或11S调节因子的蛋白酶体激活蛋白,由两个同源亚基(α和β)组成,还有一种单独但相关的蛋白被称为Ki抗原或PA28γ,它们的特性已得到表征。为了探究这些蛋白质之间的功能关系,利用针对源自它们序列的肽段的三种不同抗血清,通过免疫荧光和免疫电子显微镜对NT2克隆D1人神经前体细胞以及HeLa S3细胞进行标记。结果发现,PA28α和PA28β抗血清均标记细胞质和核仁。相比之下,PA28γ抗血清标记细胞核但不标记核仁,而在细胞质中它标记两类不同的结构,被鉴定为微管样延伸和最有可能是自噬体的包涵体。后者不含有蛋白酶体δ亚基抗原。微管样结构与β-微管蛋白共定位,可被诺考达唑分散,且不受布雷菲德菌素A处理的影响。PA28α和PA28β在细胞中共定位,而PA28γ具有不同的分布。与蛋白酶体复合的PA28γ可能具有除激活之外的其他功能,或者除激活功能之外还具有其他功能,并且可能还具有不依赖蛋白酶体的功能。

相似文献

1
Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells.蛋白酶体激活剂(PA28)亚基α、β和γ(Ki抗原)在NT2神经前体细胞和HeLa S3细胞中的情况。
Eur J Cell Biol. 1998 Oct;77(2):151-60. doi: 10.1016/s0171-9335(98)80083-6.
2
Growth retardation in mice lacking the proteasome activator PA28gamma.缺乏蛋白酶体激活剂PA28γ的小鼠生长发育迟缓。
J Biol Chem. 1999 Dec 31;274(53):38211-5. doi: 10.1074/jbc.274.53.38211.
3
Structural and functional properties of proteasome activator PA28.蛋白酶体激活剂PA28的结构与功能特性
Mol Biol Rep. 1997 Mar;24(1-2):89-93. doi: 10.1023/a:1006897801858.
4
Properties of the nuclear proteasome activator PA28gamma (REGgamma).核蛋白酶体激活剂PA28γ(REGγ)的特性
Arch Biochem Biophys. 2000 Nov 15;383(2):265-71. doi: 10.1006/abbi.2000.2086.
5
In vivo characterization of the proteasome regulator PA28.蛋白酶体调节剂PA28的体内特性研究
J Biol Chem. 1996 Jul 26;271(30):18237-42. doi: 10.1074/jbc.271.30.18237.
6
Properties of the beta subunit of the proteasome activator PA28 (11S REG).蛋白酶体激活剂PA28(11S REG)β亚基的特性
Arch Biochem Biophys. 2000 Dec 1;384(1):174-80. doi: 10.1006/abbi.2000.2112.
7
Proteasome activator subunit PA28 alpha and related Ki antigen (PA28 gamma) are absent from the nuclear fraction purified by sucrose gradient centrifugation.
Int J Biochem Cell Biol. 1999 Feb;31(2):273-6. doi: 10.1016/s1357-2725(98)00117-4.
8
The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition.蛋白酶体调节剂PA28α/β可增强抗原呈递,而不影响20S蛋白酶体亚基组成。
Eur J Immunol. 2000 Dec;30(12):3672-9. doi: 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B.
9
Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome.PA28的两个同源亚基的一级结构,PA28是一种γ干扰素诱导的20S蛋白酶体蛋白激活剂。
FEBS Lett. 1995 Jun 5;366(1):37-42. doi: 10.1016/0014-5793(95)00492-r.
10
PA28 subunits of the mouse proteasome: primary structures and chromosomal localization of the genes.小鼠蛋白酶体的PA28亚基:基因的一级结构和染色体定位
Immunogenetics. 1997;46(4):337-44. doi: 10.1007/s002510050281.

引用本文的文献

1
SUMOylation-mediated PSME3-20 proteasomal degradation of transcription factor CP2c is crucial for cell cycle progression.SUMOylation 介导的 PSME3-20 蛋白酶体降解转录因子 CP2c 对于细胞周期进程至关重要。
Sci Adv. 2023 Jan 27;9(4):eadd4969. doi: 10.1126/sciadv.add4969.
2
Regulation of Life & Death by REGγ.REGγ 调控生死。
Cells. 2022 Jul 23;11(15):2281. doi: 10.3390/cells11152281.
3
Localized Proteasomal Degradation: From the Nucleus to Cell Periphery.局部化的蛋白酶体降解:从细胞核到细胞外周。
Biomolecules. 2022 Jan 29;12(2):229. doi: 10.3390/biom12020229.
4
Increased expression of PSME2 is associated with clear cell renal cell carcinoma invasion by regulating BNIP3‑mediated autophagy.PSME2 的表达增加通过调节 BNIP3 介导的自噬与肾透明细胞癌的侵袭有关。
Int J Oncol. 2021 Dec;59(6). doi: 10.3892/ijo.2021.5286. Epub 2021 Nov 15.
5
PA28γ: New Insights on an Ancient Proteasome Activator.PA28γ:古老蛋白酶体激活剂的新见解。
Biomolecules. 2021 Feb 5;11(2):228. doi: 10.3390/biom11020228.
6
The Ubiquitin-Proteasome System in Immune Cells.免疫细胞中的泛素-蛋白酶体系统。
Biomolecules. 2021 Jan 5;11(1):60. doi: 10.3390/biom11010060.
7
Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3.肿瘤通过过表达蛋白酶体激活剂 PSME3 来逃避免疫监视。
Oncoimmunology. 2020 May 21;9(1):1761205. doi: 10.1080/2162402X.2020.1761205.
8
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.蛋白酶体作为一个具有多种治疗潜力的可药物靶标:有切与非切的两面性。
Pharmacol Ther. 2020 Sep;213:107579. doi: 10.1016/j.pharmthera.2020.107579. Epub 2020 May 19.
9
Regulation of Proteasome Activity by (Post-)transcriptional Mechanisms.通过(转录后)机制对蛋白酶体活性的调控
Front Mol Biosci. 2019 Jul 16;6:48. doi: 10.3389/fmolb.2019.00048. eCollection 2019.
10
FBXL19 recruits CDK-Mediator to CpG islands of developmental genes priming them for activation during lineage commitment.FBXL19 将 CDK-Mediator 募集到发育基因的 CpG 岛上,为谱系确定期间的基因激活做好准备。
Elife. 2018 May 29;7:e37084. doi: 10.7554/eLife.37084.